{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:48Z","timestamp":1792790508215,"version":"4.5.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The purpose of this study was to investigate the efficacy and safety of triple therapy with transcatheter arterial chemoembolization (TACE)\/hepatic arterial infusion chemotherapy (HAIC) in patients with advanced hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search of multiple databases ending with publications from May 2024 was conducted. Interventions with TACE\/HAIC combined with targeted immunotherapy versus targeted immunotherapy and patients with advanced HCC were included in this meta-analysis. Data from the 13 included studies, encompassing 2, 662 patients with HCC, were pooled using fixed- or random-effects models. The results are reported as hazard ratios (HRs) or risk ratios (RRs) with corresponding 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In contrast to targeted immunotherapy, TACE\/HAIC combined targeted immunotherapy can significantly improve overall survival (OS), progression-free survival (PFS) the disease control rate (DCR), and the objective response rate (ORR) in patients with advanced HCC. At the same time, the overall incidence of treatment-related adverse events (AEs) and treatment-related AEs of grade 3 or greater also increased, but only a few of the specific treatment-related AEs increased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given that combined TACE\/HAIC with targeted immunotherapy significantly improves patient OS, PFS, DCR, and ORR, it may become standard for the treatment of patients with advanced HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1669460","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:46:06Z","timestamp":1763556366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of TACE\/HAIC combined with targeted immunotherapy versus targeted immunotherapy for advanced hepatocellular carcinoma: a meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuting","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8740976","article-title":"Immunotherapy for hepatocellular carcinoma: current advances and future expectations","volume":"2018","author":"Xie","year":"2018","journal-title":"J Immunol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0150","article-title":"Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma","volume":"22","author":"Xiang","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-023-10084-4","article-title":"Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers","volume":"42","author":"Wang","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00500-6","article-title":"Author correction: hepatocellular carcinoma","volume":"10","author":"Llovet","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: A multicenter, phase III, randomized study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042220-021121","article-title":"Hepatocellular carcinoma immunotherapy","volume":"73","author":"Sperandio","year":"2022","journal-title":"Annu Rev Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S544589","article-title":"Tumor compression of the hepatic or portal vein predicts the presence of microvascular invasion and satellite nodules in hepatocellular carcinoma: A retrospective study","volume":"12","author":"Wang","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S462168","article-title":"Portal venous and hepatic arterial coefficients predict post-hepatectomy overall and recurrence-free survival in patients with hepatocellular carcinoma: A retrospective study","volume":"11","author":"Li","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A multicenter retrospective study","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: A retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188638","article-title":"The progress of immune checkpoint therapy in primary liver cancer","volume":"1876","author":"Zheng","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S386672","article-title":"Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma","volume":"9","author":"Huang","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231166765","article-title":"Transarterial chemoembolization combined with PD-1 inhibitors plus lenvatinib showed improved efficacy for treatment of unresectable hepatocellular carcinoma compared with PD-1 inhibitors plus lenvatinib","volume":"22","author":"Wang","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10502-3","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma","volume":"17","author":"Xin","year":"2023","journal-title":"Hepatol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1515\/oncologie-2022-1019","article-title":"Treatment with camrelizumab plus tyrosine kinase inhibitors with or without TACE for intermediate-advanced hepatocellular carcinoma: a clinical efficacy and safety study","volume":"25","author":"Yin","year":"2023","journal-title":"Oncologie"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-024-03724-x","article-title":"Transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors versus tyrosine kinase inhibitors plus immune checkpoint inhibitors in unresectable hepatocellular carcinoma with first- or lower-order portal vein tumor thrombosis","volume":"47","author":"Zhang","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2023.09.001","article-title":"Role of transarterial chemoembolization in the era of tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy for unresectable hepatocellular carcinoma: A retrospective propensity score matched analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Acad Radiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","article-title":"Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma","volume":"11","author":"Mei","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12885-024-12233-6","article-title":"HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study","volume":"24","author":"Chang","year":"2024","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16463","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE","volume":"39","author":"Diao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001378","article-title":"Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors","volume":"110","author":"Guan","year":"2024","journal-title":"Int J Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10672-8","article-title":"Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis","volume":"18","author":"Li","year":"2024","journal-title":"Hepatol Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: sorafenib plus TACE vs TACE alone randomized clinical trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S461630","article-title":"Transarterial chemoembolization combined with atezolizumab plus bevacizumab versus transarterial chemoembolization alone in intermediate-stage hepatocellular carcinoma: A multicenter retrospective study","volume":"11","author":"Zheng","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12032-023-02012-x","article-title":"Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma","volume":"40","author":"Long","year":"2023","journal-title":"Med Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1265240","article-title":"Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"13","author":"Kim","year":"2023","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: A review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: A review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12885-024-12355-x","article-title":"Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma","volume":"24","author":"Xiao","year":"2024","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S431917","article-title":"Tyrosine kinase inhibitors plus anti-PD-1 antibodies with hepatic arterial infusion chemotherapy or transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"10","author":"Yu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000654","article-title":"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study","volume":"109","author":"Deng","year":"2023","journal-title":"Int J Surg"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S436211","article-title":"Comparable clinical outcomes between transarterial chemoembolization or hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and PD-1 inhibitors in unresectable hepatocellular carcinoma","volume":"10","author":"Long","year":"2023","journal-title":"J Hepatocell Carcinoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669460\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:46:07Z","timestamp":1763556367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669460\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":46,"alternative-id":["10.3389\/fonc.2025.1669460"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1669460","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1669460"}}